Director at Anika Therapeutics (NASDAQ: ANIK) receives 10,402 RSU grant

Rhea-AI Filing Summary

Fischetti Gary P reported acquisition or exercise transactions in this Form 4 filing.

Anika Therapeutics director Gary P. Fischetti received a grant of 10,402 shares of common stock in the form of restricted stock units (RSUs). The award carried no cash purchase price and increases his direct holdings to 52,015 shares after the grant.

Each RSU represents a right to receive one share of Anika Therapeutics common stock. The RSUs vest in full on the earlier of the company’s 2027 annual stockholder meeting or June 18, 2027, aligning the director’s compensation with long-term shareholder interests.

Insights

Equity compensation analyst

Routine director RSU grant increases equity-based compensation with long-term vesting.

The filing shows Gary P. Fischetti, a director of Anika Therapeutics, receiving 10,402 restricted stock units at no cash cost. This is a compensation-related acquisition rather than an open-market purchase, so it carries limited signaling value about his short-term view of the stock.

The RSUs vest in full on the earlier of the 2027 annual stockholder meeting or June 18, 2027, encouraging longer-term board alignment with shareholders. After the grant, Fischetti directly holds 52,015 shares, indicating a meaningful ongoing equity stake while remaining a routine governance practice.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Fischetti Gary P

Role null

Type	Security	Shares	Price	Value
Grant/Award	Common Stock	10,402	$0.00	--

Holdings After Transaction: Common Stock — 52,015 shares (Direct, null)

Footnotes (1)

1. [object Object]

Key Figures

RSU grant size: 10,402 shares Price per share for grant: $0.00 per share Shares held after grant: 52,015 shares +1 more

4 metrics

RSU grant size 10,402 shares Restricted stock units granted to director on June 18, 2026

Price per share for grant $0.00 per share Equity award, no cash purchase price

Shares held after grant 52,015 shares Director’s direct holdings following RSU award

Vesting date latest June 18, 2027 Full vesting no later than this date

Key Terms

restricted stock units ("RSUs"), contingent right, annual meeting of the Company's stockholders, Form 4

4 terms

restricted stock units ("RSUs") financial

"These shares represent restricted stock units ("RSUs"). Each RSU represents a contingent right"

Restricted stock units (RSUs) are a company promise to give an employee shares of stock (or cash equivalent) in the future, but only after certain conditions—usually staying with the company for a set time or hitting performance goals—are met. Investors watch RSUs because when they vest they increase the number of shares outstanding and can lead insiders to sell shares, affecting share price, company dilution and the true cost of employee pay.

contingent right financial

"Each RSU represents a contingent right to receive one share of the Company's common stock."

annual meeting of the Company's stockholders regulatory

"The RSUs vest in full on the earlier of the 2027 annual meeting of the Company's stockholders or June 18, 2027."

Form 4 regulatory

"INSIDER FILING DATA (Form 4):"

Form 4 is a official document that company insiders, such as executives or major shareholders, file with regulators whenever they buy or sell company shares. It provides transparency about how those with inside knowledge are trading, helping investors see if insiders are confident in the company's prospects or may be selling for personal reasons. This information can influence investor decisions by revealing insiders' perspectives on the company's value.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

Available on EDGAR 06/23/2026 - 04:31 PM Accepted by SEC EDGAR 06/23/2026 - 04:30 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Fischetti Gary P

(Last) (First) (Middle)

C/O ANIKA THERAPEUTICS, INC.

32 WIGGINS AVENUE

(Street)

BEDFORD MASSACHUSETTS 01730

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Anika Therapeutics, Inc. [ ANIK ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/18/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	06/18/2026		A		10,402(1)	A	$0	52,015	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. These shares represent restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Company's common stock. The RSUs vest in full on the earlier of the 2027 annual meeting of the Company's stockholders or June 18, 2027.

	/s/ Gary P. Fischetti	06/23/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)